News | February 03, 2024
Abbott India posts Q3 FY24 PAT at Rs. 310.98 Cr
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Thyrocare Technologies has reported total income of Rs. 137.47 crores during the period ended December 31, 2023
Dr. Lal Path Labs has reported total income of Rs. 557.2 crores during the period ended December 31, 2023
GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023
Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023
Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Subscribe To Our Newsletter & Stay Updated
